Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several ...
The FDA intends to place a black box label—its most serious warning—on COVID-19 vaccines, according to reporting by CNN. It ...
Zacks Investment Research on MSN
Here is what to know beyond why Novavax, Inc. (NVAX) is a trending stock
Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced ...
On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older. The Centers for Disease Control and Prevention and its advisory panel ...
Shares of Novavax fell more than 25% in after-hours trading Tuesday, following a dismal fourth quarter earnings report and a warning from the Covid vaccine maker that uncertainty over future funding ...
Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...
Novavax, Inc. recently announced at the Jefferies London Healthcare Conference 2025 that it is shifting its focus from direct COVID-19 commercial operations to an expanded research and development ...
Novavax (NVAX-0.94%) stock is up around 3,500% so far this year. And that's after a significant recent decline. Earlier this month, shares of Novavax were up nearly 4,400% year to date. These ...
Shares of COVID-19 vaccine maker Novavax cratered Tuesday as the U.S. biotech company slashed its sales forecast due to a slump in demand for its shots. The company's stock dived 31% after it cut its ...
The Food and Drug Administration announced Tuesday it had authorized Novavax's updated COVID-19 vaccine, adding a third option for Americans ages 12 and older looking for a new shot this fall and ...
Novavax's closely watched COVID-19 vaccine is on track for full approval after additional discussions with the FDA, the company said Wednesday. The news sent company shares soaring more than 21% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results